|
14 Jun 2019 |
FDA Approves Amgen And Allergan's KANJINTITM (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab)
|
|
14 Jun 2019 |
UCB’s Key Pipeline Molecule Bimekizumab Demonstrated Improved Outcomes for Ankylosing Spondylitis Patients
|
|
13 Jun 2019 |
Update on Etigilimab (TIGIT) Partnership
|
|
13 Jun 2019 |
Entasis Therapeutics Announces Initial ETX0282 Phase 1 Results
|
|
13 Jun 2019 |
First-in-Human Data Presented from Phase 1a Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology
|
|
13 Jun 2019 |
Lumosa to Initiate Phase 2 Human Clinical Trial in the US and Taiwan for Its LT3001, A Novel Drug for the Treatment of Acute Ischemic Stroke
|
|
13 Jun 2019 |
AbCellera Announces Therapeutic Antibody Discovery Collaboration with Gilead in Infectious Disease
|
|
13 Jun 2019 |
Resolve Therapeutics Announces RSLV-132 Significantly Reduces Fatigue in Phase II Study of Patients with Sjögren’s Syndrome
|
|
13 Jun 2019 |
Noveome Biotherapeutics, Inc. Announces the First Patient Dosed in Phase 2 Open Label Clinical Trial Evaluating Topical Ocular Delivery of ST266 For the Treatment of Persistent Corneal Epithelial Defects
|
|
13 Jun 2019 |
Corvidia Therapeutics Initiates Phase 2b Dose-Finding Study for Ziltivekimab
|
|
13 Jun 2019 |
Progenics Pharmaceuticals Doses First Patient in Phase 2 Clinical Study of 1095 Radiotherapy for the Treatment of Metastatic Prostate Cancer
|
|
13 Jun 2019 |
First Patient Dosed with Gevokizumab in Collaborator Clinical Study in Metastatic Colorectal Cancer, Gastroesophageal Cancer, and Renal Cell Carcinoma
|
|
13 Jun 2019 |
Bone Therapeutics’ allogeneic cell therapy product, ALLOB, meets primary endpoints in Phase IIa study in patients undergoing a lumbar spinal fusion procedure
|
|
13 Jun 2019 |
Servier announces European Commission decision to convert conditional approval into standard marketing authorization in patients with aggressive non-Hodgkin B-cell lymphoma for PIXUVRI® (pixantrone)
|
|
13 Jun 2019 |
Terns Pharmaceuticals Initiates a Phase 1 Clinical Trial of TERN-101
|
|
13 Jun 2019 |
Savara Announces Results of IMPALA, a Phase 3 Study of Molgradex for the Treatment of Autoimmune Alveolar Pulmonary Proteinosis (aPAP)
|
|
13 Jun 2019 |
Phase III PEMPHIX Study Showed That Genentech’s Rituxan (Rituximab) is Superior to Standard of Care in Achieving Sustained Remission in Patients with Pemphigus Vulgaris
|
|
12 Jun 2019 |
Constellation Pharmaceuticals Presentation Highlights Enhanced EZH2 Target Engagement, Leading to Second-Generation EZH2 Inhibitor CPI-0209
|
|
12 Jun 2019 |
Tolero Pharmaceuticals Announces First Patient Dosed with Investigational Agent TP-0903 in Phase 1/2 Study in Patients with Previously Treated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
|
|
12 Jun 2019 |
OnKure and CU Cancer Center Announce First Patient Enrolled in Clinical Trial of OKI-179, a Potent and Selective HDAC Inhibitor
|
